On Oct. 27, 2022, Inovio Pharma announced that it has discontinued its internally funded efforts to develop INO-4800 as a COVID-19 heterologous booster vaccine. The decision followed INOVIO’s comprehensive review of its portfolio, market conditions, and global demand for COVID-19 vaccines.

INO-4800 is a DNA medicine product candidate that has been studied as a vaccine candidate for COVID-19. It continues to be one of the vaccines being investigated by the World Health Organization as part of their Solidarity Trial Vaccines, which was an international, multi-center, multi-vaccine, adaptive, shared placebo, event-driven, individually randomized controlled clinical trial that aims to evaluate the efficacy and safety of promising new COVID-19 vaccines.

INOVIO’s partner in China, Advaccine, will continue to develop INO-4800 as a COVID-19 heterologous booster vaccine with its own resources. Advaccine is currently analyzing the data from its heterologous boost trial with INO-4800. Any future updates on this trial will be provided by Advaccine.